Prediction of breast cancer outcome using a fulvestrant-resistant gene signature identified by our ZF-TF-based approach.
Patients were stratified using a metagene that was formed by averaging the expression of the 72 genes constituting the common signature for the fulvestrant resistance phenotype (i.e., the genes of cluster 5 in Fig. 3A). Tumors with metagene values below the median were defined as the “fulvestrant-resistant metagene” and the others as the “fulvestrant-sensitive metagene.” Kaplan-Meier curves for distant metastasis-free survival or death-from-relapse-free survival using the metagene are based on clinical data described by (A) Wang et al., N = 286 , (B) van de Vijver et al., N = 295 , (C) Chin et al., N = 130 , (D) Miller et al., N = 251  and (E) Sotiriou et al., N = 189 . p-values are one-sided.